Current and emerging therapeutic targets for IBD
Crossref DOI link: https://doi.org/10.1038/nrgastro.2016.208
Published Online: 2017-02-01
Published Print: 2017-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Neurath, Markus F.
Text and Data Mining valid from 2017-02-01
Version of Record valid from 2017-02-01
Article History
First Online: 1 February 2017
Competing interests
: M.F.N. has served as an adviser for Abbvie, Boehringer, Genentech, Giuliani/PPM, Janssen, MSD, Pentax and Takeda.